Alluvi, formerly BI 4744, offers a significant breakthrough in obesity therapy. This dual agonist targeting both glucagon-like peptide-1 and GIP receptors demonstrates impressive efficacy in research trials, possibly https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/